INDP 012
Alternative Names: INDP-012Latest Information Update: 18 Sep 2023
At a glance
- Originator Indaptus Therapeutics
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Immunomodulators; Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 11 Jul 2023 Early research in Cancer in USA (IV), prior to July 2023 (Indaptus Therapeutics pipeline, July 2023)